Effect of sibutramine and of cognitive‐behavioural weight loss therapy in obesity and subclinical binge eating disorder
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Aim: In this randomized, double‐blind, placebo‐controlled study, the effect of sibutramine and cognitive‐behavioural weight loss (cognitive‐BWL) treatment was assessed in obese subjects with and without subclinical binge eating disorder (sBED). Methods: Seventy‐three obese participants were recruited from the community, 29 with and 44 without sBED. Subjects were randomly assigned to a 16‐week treatment with either sibutramine or placebo while simultaneously participating in a cognitive‐behavioural weight loss treatment. Results: Intent‐to‐treat analysis showed moderate weight loss after treatment in all subject groups. Treatment with BWL programs and sibutramine leads to a higher weight loss in all subjects compared with that in patients who had undergone BWL programs alone. Subjects with sBED significantly reduced their binge episodes during treatment, but with no augmenting effect of sibutramine. Discussion: Our results yield further evidence that sBED is associated with characteristics comparable with full‐syndrome BED, significantly differing from those of obesity alone. These findings call for a systematic assessment of eating behaviour before starting obesity treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cognitive–behavioral self-help for binge eating disorder: A controlled effectiveness study.
Carter, J. C., & Fairburn, C. G. (1998) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.66.4.616 · Cited by 252
Cited by
Interventions for treating obesity in children
Oude Luttikhuis, H., Baur, L., Jansen, H., Shrewsbury, V. A., O'Malley, C., Stolk, R. P., & Summerbell, C. D. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001872.pub2 · Cited by 1,531
RetractedAigner, M., Treasure, J., Kaye, W., Kasper, S., & The WFSBP Task Force on Eating Disorders (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.602720 · Cited by 207
“(2000) conducted a 6-week double blind placebo controlled trial in 34 patients (8 dropouts) with sertraline with signifi cant reduction in frequency of binge eating, CGI, and BMI. O ̀ Reardon et al.(2006) performed a 8-week randomized controlled trial in 34 patients with night eating syndrome.”
BackgroundMethodInfluentialPharmacological approaches to the management of binge eating disorder
Brownley, K. A., Peat, C. M., La Via, M., & Bulik, C. M. (2015) · Drugs · doi:10.1007/s40265-014-0327-0 · Cited by 78
“Eight of these studies are not discussed further: seven [69–75] used drugs (d-fenfluramine, sibutramine, rimonabant) that are no longer available in the US market, and one [76] failed to present the results separately in BED and non-BED participants.”
BackgroundCurrent and emerging drug treatments for binge eating disorder
Reas, D. L., & Grilo, C. M. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.879291 · Cited by 52
“Previously published RCTs investigating D-fenfluramine [20], sibutramine [21-24] and rimonabant [25] and two ongoing clinical trials (NCT00829283 and NCT00537810) were not considered in the review because these medications were withdrawn from the market due to adverse events and D.”
Neri, L. D. C. L., Mariotti, F., Guglielmetti, M., Fiorini, S., Tagliabue, A., & Ferraris, C. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1250683 · Cited by 13
Metadata
- Authors
- Bauer, C., Fischer, A., & Keller, U.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2005-05-03
- Volume
- 8
- Issue
- 3
- Pages
- 289-295
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2166488405
- Cited by
- 26
- References
- 1
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of sibutramine and of cognitive‐behavioural weight loss therapy in obesity and subclinical binge eating disorder. https://app.cochat.ai/papers/10.1111/j.1463-1326.2005.00504.x
- The paper
- Bauer, C., Fischer, A., & Keller, U. (2006). Effect of sibutramine and of cognitive‐behavioural weight loss therapy in obesity and subclinical binge eating disorder. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2005.00504.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.